A Call to Accountability: Reporting Outcomes in Vascularized Composite Allotransplantation

Area of Science:

• Transplantation research ethics
• Clinical trial reporting standards
• Vascularized composite allotransplantation (VCA) outcomes

Background:

• Vascularized composite allotransplants (VCAs) in the US are primarily research-based.
• International ethical statements emphasize comprehensive clinical trial result disclosure.
• Existing US policies mandate VCA data submission only from September 2015 onwards.

Purpose of the Study:

• To highlight the ethical obligation to report all VCA outcomes.
• To advocate for the inclusion of pre-September 2015 VCA data in reporting requirements.
• To encourage adherence to international research integrity standards.

Main Methods:

• Review of international ethical statements on clinical trial disclosure.
• Analysis of current Organ Procurement and Transplant Network (OPTN) VCA data submission policies.
• Comparison of reporting requirements for pre- and post-September 2015 VCAs.

Main Results:

• Nearly all US VCAs have been conducted as research, creating an ethical duty to report outcomes.
• International standards require reporting of positive, negative, and inconclusive results.
• Current OPTN policy makes reporting of the majority of US VCA data (pre-September 2015) optional.

Conclusions:

• There is an ethical imperative to report all VCA outcomes, including those from before September 2015.
• The OPTN and the American Society of Reconstructive Transplantation should enforce comprehensive data reporting.
• Accountability for reporting long-term VCA outcomes is essential for research integrity and patient welfare.